In p16TdTom mice given doxorubicin-induced senescence, lung tdTomato (p16) signal fell from 7.3% (vehicle) to 1.1% with GinA (p=0.014) and 0.8% with modGinA (one-way ANOVA p=0.0086 overall); kidney changes were non-significant and brain/liver unchanged . In 79-80-week-old C57BL/6JN mice (vehicle/GinA/modGinA, n=14,14,14 with 3 deaths censored), modGinA reduced IL-2, IL-5 (9 weeks) and IL-5/IL-6 at washout; tissue cytokines were unchanged. Metabolomics showed 174 serum metabolites differing during treatment, EPA-containing phosphoethanolamines rising with modGinA, liver NADP+ increasing, and lipid classes (CE, Cer, SM, PE, PA) shifting . Behavioral tests were largely null; a single rotarod trial 3 comparison (p=0.0467) is fragile and uncorrected.
Reported group means from the paper; individual spread, SE and exact modGinA p-value are incompletely reported in the supplied text, so error bars cannot be drawn.
Key inferential gaps: (1) The vehicle (high-oleic sunflower oil) itself changed 268 metabolites over 10 weeks β the authors acknowledge this, but it means treatment-vs-vehicle differences partly reflect two different lipid exposures, not GinA pharmacology alone. (2) Aged-mouse cytokine effects and doxorubicin-model senolysis were measured in different cohorts; no direct link between IL-6 reduction and senescent-cell clearance within one animal is shown. (3) Mechanistic attribution to AMPK/NAD+ is interpretive β only NADP+ changed significantly. (4) The patent conflict (five co-inventors among authors) is disclosed but creates financial-incentive bias risk favoring positive reporting . Prior independent work supports anti-inflammatory plausibility of GinA (NF-ΞΊB/IKK suppression in endothelial cells; p70S6K inhibition improving insulin signaling) , but no human translational evidence exists. Confidence: moderate for tissue-level senescence-marker effects in mice; low for any therapeutic implication.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.